Search All

Lab Test Dictionary

Drug Profile, Expanded Targeted Panel, Urine (3005060)

Methodology

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Specimen Type

Urine

Performing Lab

ARUP

Epic ID

Other Reference Test

Lab Test Days

Monday and Friday

Standard TAT

1-8 Days

Collection Information

Specimen Required

2-4 mL Random Urine (no additives)

Container Type

Sterile Container

Processing Information - Lab Use Only

Transport Temperature

Refrigerated-OK/Frozen-OK

Specimen Stability

Room Temp: 1 Day; Refrigerated: 2 Weeks (Preferred); Frozen: 2 Months

Rejection Criteria

Specimens exposed to repeated freeze/thaw cycles

Test Volume Required

4 mL Random Urine

Minimum Test Volume

2 mL Random Urine

Processing Instructions

Complete an ARUP requisition form and submit urine refrigerated with daily Apollo Courier pick up.

Included Tests

Use to detect drug exposure from among a targeted list of prescriptions, over-the-counter medications, and illicit drugs; for a complete list of drugs and drug metabolites detected, refer to Additional Technical Information. Not recommended to determine medication compliance or to assess for undisclosed drug/substance use in the context of pain management, substance use disorder treatment, or any other pharmacotherapies involving controlled substances. The drug screen panel can detect 127 drugs and drug metabolites by LC-MS/MS. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory. This assay is for medical purposes only; not valid for forensic use. Note: If a specimen drug class is reported as positive, the test will report the confirmed component from the comprehensive drug class at no additional charge.